(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MojyR4VtdCCYaXHibYxqfHliQYPzZZk> NF7HdW8zPTBxNUCwM|ExODBibl2= NEjpV4QzPC92OD:3NkBp NU\ENodFTE2VTx?= NXPtS3Y4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MUSyOlcxPzh6MR?=
BCPAP NHjSPJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1f2SVI2OC93MECvNVAxOCCwTR?= MVKyOE81QC95MjDo MoLYSG1UVw>? NWjjV41YcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? Mk\oNlY4ODd6OEG=
K1  NGn1VFlE\WyuIFP5Z4xmKEG|c3H5 NWDSSJVPOjVyL{WwNE8yODByIH7N MljBO|IhcA>? M1[xTGROW09? M4jW[oFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= M4DrNFI3PzB5OEix
BCPAP M1zYbGNmdGxiQ4njcIUhSXO|YYm= NX61WWg4OjVyL{WwNE8yODByIH7N M4HWW|czKGh? MkfCSG1UVw>? M{e4S4FzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= NHfzTGwzPjdyN{i4NS=>
Hep3B MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMVExKM7:TR?= M4jScFUh\A>? MXvEUXNQ NX\ifZhvUUN3ME2wMlA5KM7:TR?= NGLpVmQzPjV5NUG2Oy=>
HCCLM3 NELnXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXZNE0yOCEQvF2= NFztW3I2KGR? Mo\HSG1UVw>? NVH2TWptUUN3ME2wMlE1KM7:TR?= M4jJclI3PTd3MU[3
HuH7 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMVExKM7:TR?= NF\JZYQ2KGR? M3zlZmROW09? NYLXdodVUUN3ME2wMlIyKM7:TR?= NX7BRY9QOjZ3N{WxOlc>
HepG2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqwMVExKM7:TR?= NUDWRpdqPSCm MVvEUXNQ NWjSNGQ{UUN3ME2wMlM1KM7:TR?= NWPwfZhsOjZ3N{WxOlc>
SMMC7721 NHXhRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMVExKM7:TR?= NVXTd3J7PSCm M4D1SmROW09? NVXse3dwUUN3ME2wMlQyKM7:TR?= M2LaWFI3PTd3MU[3
BEL7402 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofzNE0yOCEQvF2= MYG1JIQ> MXrEUXNQ MVjJR|UxRTBwNEeg{txO MlfZNlY2PzVzNke=
MHCC97H NWGwN3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PtVFAuOTBizszN M2rZTlUh\A>? NGDsSo1FVVOR MWLJR|UxRTBwNEGg{txO MlHJNlY2PzVzNke=
Hep3B MnPIR4VtdCCFeXPs[UBCe3OjeR?= NXrWU3A4OC5zL{CuOU8zNjVizszN M4rFZlQ5KGh? M2jOUGROW09? NGLifWVt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NYrRVpJ4OjZ3N{WxOlc>
HCCLM3 MWLD[YxtKEO7Y3zlJGF{e2G7 M1Po[FAvOS9yLkWvNk42KM7:TR?= MlywOFghcA>? NUTLXZNJTE2VTx?= MXfs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MlvJNlY2PzVzNke=
Hep3B NH3wcFNCeG:ydH;zbZMhSXO|YYm= NWDpRlNHOC5zL{CuOU8zNjVizszN NV:zR4ppPDhiaB?= MorvSG1UVw>? NEH2cXRi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj M{K2PVI3PTd3MU[3
HCCLM3 NYnq[WZpSXCxcITvd4l{KEG|c3H5 MYqwMlEwOC53L{KuOUDPxE1? NH:3Tog1QCCq NWnHb4J{TE2VTx?= NEHMeJJi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj NXHDOGxZOjZ3N{WxOlc>
A549 M4fEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDFZVVSOC5zLUGwJO69VQ>? M2DCNlczKGh? NGHl[G1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHYNlY1OTV{MkW=
H157 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPqNE4yNTFyIN88US=> NUHpOVA1PzJiaB?= MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4HMNlI3PDF3MkK1
H1299 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMlEuOTBizszN NG\EVGI4OiCq MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1TI[|I3PDF3MkK1
A549 NX60WYVLTnWwY4Tpc44hSXO|YYm= NXS5VG9YOS9{LkWvOUDPxE1? Mn;KNVIhcA>? NVfkdIpjyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= MXGyOlQyPTJ{NR?=
H1299 NH\GVJpHfW6ldHnvckBCe3OjeR?= MkfsNU8zNjVxNTFOwG0> NEi3b3EyOiCq NHfMcYTDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| MVeyOlQyPTJ{NR?=
H157 NHTVcJdHfW6ldHnvckBCe3OjeR?= M3ruc|EwOi53L{Wg{txO MkH2NVIhcA>? Mljz[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w NGntXoUzPjRzNUKyOS=>
H1299 M1f4dGZ2dmO2aX;uJGF{e2G7 NVr0ZWhpOS9{LkWvOUDPxE1? M1\F[lEzKGh? NXTHfoRY\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u MojLNlY1OTV{MkW=
C8161 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWmwMVIh|ryP M4jnNlQh\A>? MXzEUXNQ NH;4Vnll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVyzWJU{OjZ|OUeyNlM>
Mel285 NIPnZlVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVvwbJhoOC1{IN88US=> MlWxOEBl MV\EUXNQ Ml73[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3LLOFI3Ozl5MkKz
Mel290 MoflR4VtdCCYaXHibYxqfHliQYPzZZk> MnXBNE0zKM7:TR?= MVu0JIQ> NUH5ZYtjTE2VTx?= MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3z6blI3Ozl5MkKz
92.1 MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXywMVIh|ryP M2\1fVQh\A>? MoPuSG1UVw>? NWfU[nRR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEDyeJkzPjN7N{KyNy=>
Omm1.3 NHixXlNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jnUlAuOiEQvF2= MnqyOEBl NX\UbXNjTE2VTx?= MX;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1Pqb|I3Ozl5MkKz
Mel202 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUWwMVIh|ryP NWGyXY5KPCCm MX7EUXNQ NFrpU2hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWmyOlM6PzJ{Mx?=
Mel270 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnaWWxwOC1{IN88US=> MoLTOEBl Mo[xSG1UVw>? MmfC[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NG\wRVkzPjN7N{KyNy=>
Omm1 NG\6cHhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVmwMVIh|ryP NEC1cYY1KGR? M1\YZ2ROW09? NEKwOGRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF7J[3kzPjN7N{KyNy=>
92.1 M3r1WWFxd3C2b4Ppd{BCe3OjeR?= MV:1NFAhdk1? NEPWSJg1QCCq NEOzN3lFVVOR NWHCeYozcW6mdXPld{BieG:ydH;zbZM> M2n5blI3Ozl5MkKz
Omm1.3 MmS3RZBweHSxc3nzJGF{e2G7 NYO2OZRwPTByIH7N NGXrW3I1QCCq MorXSG1UVw>? NIDlNGNqdmS3Y3XzJIFxd3C2b4Ppdy=> MYOyOlM6PzJ{Mx?=
92.1 MVjD[YxtKEO7Y3zlJGF{e2G7 NWfaSIw5PTByIH7N MmfxNlQwPDhxN{KgbC=> NHLJSodFVVOR NVXVcnRLcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NXf5cZV1OjZ|OUeyNlM>
Omm1.3 MUDD[YxtKEO7Y3zlJGF{e2G7 NHrISGo2ODBibl2= MX6yOE81QC95MjDo MX3EUXNQ M37qNolv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NVnJV|NMOjZ|OUeyNlM>
A549 NFnQR45HfW6ldHnvckBCe3OjeR?= Mn6zNVAxNzRyMD:xNFAxKG6P NF71TFYzPCCq M33nPJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NWT3WmlZOjZ{MUKxPVk>
MCF-7 MoPoSpVv[3Srb36gRZN{[Xl? MlLPNVAxNzRyMD:xNFAxKG6P MX[yOEBp MUH1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NVLPc5p4OjZ{MUKxPVk>
HEK293 MVjGeY5kfGmxbjDBd5NigQ>? Moe4NVAxNzRyMD:xNFAxKG6P M3HtUFI1KGh? NW\1d5pufXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NGDa[oIzPjJzMkG5PS=>
858 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{PwVFAuOSEQvF2= NEfrcmY2KGR? NHGwdWJFVVOR Mmr6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3LQXVI3OjB4M{Oz
DDR2L63V MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2nnWlAuOSEQvF2= M3XLRlUh\A>? M1LORWROW09? NYHJdndi\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUDqc4pPOjZ{ME[zN|M>
BE(2)-C NX[yS4lYS2WubDDWbYFjcWyrdImgRZN{[Xl? Mm\oNUDPxE1? NFT2ZZoyNTRiZB?= NWHnVmx[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NWPnWlZROjZyNke0OlQ>
IMR-32 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGPYZ|cyKM7:TR?= MkLMNU01KGR? M{DOVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MYqyOlA3PzR4NB?=
JF MlLwR4VtdCCYaXHibYxqfHliQYPzZZk> NGDhbnoyKM7:TR?= MWOxMVQh\A>? NFfKZYdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NVjsbJdEOjZyNke0OlQ>
BE(2)-M17 NGnuRZhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{DQd|Eh|ryP MXWxMVQh\A>? M{HxZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M1vXVFI3ODZ5NE[0
SK-N-SH NUnXUZMyS2WubDDWbYFjcWyrdImgRZN{[Xl? MVixJO69VQ>? MkjINU01KGR? NXK2eYVx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M{nLc|I3ODZ5NE[0
SK-N-DZ  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mnv5NUDPxE1? NUPjSXN3OS12IHS= NGfCSWdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M375SFI3ODZ5NE[0
HMC-1.1  NV[4R2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXoSYQ2NTVyMECgcm0> NFfBRmc1QCCq NXPoPYhvTE2VTx?= M4nxOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlK1NlYxPTV|MEO=
HMC-1.2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe1MVUxODBibl2= NX\3eG9NPDhiaB?= NUHTNWg5TE2VTx?= M2fydIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWqyOlA2PTNyMx?=
ROSA KIT WT  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL0[5JOPS13MECwJI5O MVS0PEBp NUW4PFFyTE2VTx?= M2jmfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGjPVlAzPjB3NUOwNy=>
ROSA KIT D816V M4f0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq1MVUxODBibl2= MlGwOFghcA>? MWnEUXNQ M{To[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEXybYUzPjB3NUOwNy=>
HMC-1.1  M4T3[mFxd3C2b4Ppd{BCe3OjeR?= MYqyNFAuPTByMDDuUS=> NEP5c5Y1QCCq M33tbWROW09? M{nKe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkGyNlYxPTV|MEO=
HMC-1.2 NVn5VJh2SXCxcITvd4l{KEG|c3H5 M2LR[VIxOC13MECwJI5O MlPMOFghcA>? NIPiRphFVVOR M2XCc4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4Gxb|I3ODV3M{Cz
ROSA KIT WT  MXLBdI9xfG:|aYOgRZN{[Xl? Mnr3NlAxNTVyMECgcm0> MkfIOFghcA>? NE\qZnNFVVOR NIjuUGZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M37KXFI3ODV3M{Cz
ROSA KIT D816V M37UUmFxd3C2b4Ppd{BCe3OjeR?= NF;OeIMzODBvNUCwNEBvVQ>? MVW0PEBp M4DyUGROW09? Mn75bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1\hUlI3ODV3M{Cz
494H MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX23NkBp Mk\USG1UVw>? NXzKdlh6UUN3ME2wMlEzOsLzMD6wNFQh|ryP MmHhNlU6PDR3Nk[=
493H Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7rVplbPzJiaB?= M2r1N2ROW09? NFXXcZpKSzVyPUCuNFQ4yrFyLkCwPUDPxE1? MoXMNlU6PDR3Nk[=
716H MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq3NkBp Mn3uSG1UVw>? MnnrTWM2OD1yLkKxNuKyOC5yM{Sg{txO NYiybodQOjV7NES1OlY>
148I NVLXSmduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnGO|IhcA>? MW\EUXNQ NHzCcYlKSzVyPUCuNlg1yrFyLkCzOUDPxE1? NFTxUmozPTl2NEW2Oi=>
98Sc MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[3NkBp MWDEUXNQ NGjyUXpKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NFj0XW8zPTl2NEW2Oi=>
89R M4XBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\MN3l{PzJiaB?= MU\EUXNQ NIL4WHRKSzVyPUCuNVI3yrFyLkCwN{DPxE1? NXWxZmZ6OjV7NES1OlY>
494L MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjHO|IhcA>? MnLLSG1UVw>? NEnMWnJKSzVyPUCuN|E4yrFyLkCxNkDPxE1? NUDUUZZWOjV7NES1OlY>
493L Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LRclczKGh? MWLEUXNQ NGXaPZhKSzVyPUCuNFUxyrFyLkCxNUDPxE1? MVSyOVk1PDV4Nh?=
148L NHXmUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS3NkBp MnnNSG1UVw>? MYLJR|UxRTBwMUS2xtExNjBzNzFOwG0> NYrFc5gyOjV7NES1OlY>
98L NG[1T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHqbVI4OiCq NVrQ[JgxTE2VTx?= NF3FZ41KSzVyPUCuN|A6yrFyLkCyPUDPxE1? NUHRSVAxOjV7NES1OlY>
OS17 NWHOdHVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp NWTic3hXTE2VTx?= M1ThWGlEPTB;MD6wO|nDuTBwMECzJO69VQ>? MXWyOVk1PDV4Nh?=
OS9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3OO|IhcA>? MV3EUXNQ MnfzTWM2OD1yLkSwOuKyOC5yMkig{txO MVWyOVk1PDV4Nh?=
MG63 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DMW|czKGh? MUHEUXNQ NIL4SYtKSzVyPUCuNVE1yrFyLkCyOUDPxE1? MXqyOVk1PDV4Nh?=
SAOS2 NGTnbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j3dVczKGh? NEPTdFVFVVOR M4\TRWlEPTB;MD6yNVfDuTBwMECzJO69VQ>? NXPWVHpOOjV7NES1OlY>
U2OS NUj1OYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jtZlczKGh? MVTEUXNQ NHPRS2VKSzVyPUCuNVk5yrFyLkCwPEDPxE1? MmHrNlU6PDR3Nk[=
SJSA-1 NHTZRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp MmL3SG1UVw>? NVLjfHlnUUN3ME2wMlExOMLzMD6wNVAh|ryP M1PNd|I2QTR2NU[2
494H MlHFRZBweHSxc3nzJGF{e2G7 NYXT[GJ2OC5{NT:wMlUwOS5yIN88US=> MlTENlQhcA>? M1r2RWROW09? MnXVbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MkPVNlU6PDR3Nk[=
148I MYDBdI9xfG:|aYOgRZN{[Xl? NFHS[nExNjJ3L{CuOU8yNjBizszN NYrMWpF[OjRiaB?= MWjEUXNQ MYrpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MXSyOVk1PDV4Nh?=
OS17 M2DJe2Fxd3C2b4Ppd{BCe3OjeR?= M1fieFAvOjVxMD61M|EvOCEQvF2= M4jm[|I1KGh? MYfEUXNQ MmHubY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MYCyOVk1PDV4Nh?=
494H NEDQTnhCeG:ydH;zbZMhSXO|YYm= NFXXV5Ey6oDLzszN MYi0PEBp NWixOmh2TE2VTx?= MVLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= M2LuSFI2QTR2NU[2
148I MoO2RZBweHSxc3nzJGF{e2G7 NXHZcpgxOeLCid88US=> M{XRe|Q5KGh? MVjEUXNQ MmXDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M1XIOFI2QTR2NU[2
OS17 MWPBdI9xfG:|aYOgRZN{[Xl? MUGx5qCK|ryP NVq0XIE3PDhiaB?= MYPEUXNQ NFK4UFRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NYXrO2dEOjV7NES1OlY>
MOLM13 M3v5TWFxd3C2b4Ppd{BCe3OjeR?= NIe0[2czPTBibl2= NIXCTGk1QCCq M{\XPWROW09? M373[Ylv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= MmTJNlUxPTN6MkW=
MV4-11  M4LtVWFxd3C2b4Ppd{BCe3OjeR?= M{XiS|I2OCCwTR?= MnL5OFghcA>? NYLFSIpNTE2VTx?= MkPVbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NI\OTJIzPTB3M{iyOS=>
MOLM13 NF\yeXhHfW6ldHnvckBCe3OjeR?= NHLqc2UzPTBibl2= M2O5R|I1KGh? NFrsO4lFVVOR NH6zOplmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= NVG5PJllOjVyNUO4NlU>
MV4-11  M4WwbWZ2dmO2aX;uJGF{e2G7 MWWyOVAhdk1? Ml;lNlQhcA>? NET6doxFVVOR NF7CXodmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= Mm\sNlUxPTN6MkW=
MOLM13 NXfwV5F1SXCxcITvd4l{KEG|c3H5 MVOyOVAhdk1? M4PRNVQ5KGh? MUXEUXNQ NEPOZ|dqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NYTGdmF4OjVyNUO4NlU>
MV4-11  NIi2cFFCeG:ydH;zbZMhSXO|YYm= NI\yUnkzPTBibl2= MmfKOFghcA>? M2LNOmROW09? NV;zdZRFcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= NUWwNXk2OjVyNUO4NlU>
Hela M16xeWNmdGxiVnnhZoltcXS7IFHzd4F6 NEOzWG0xNTVyMDDuUS=> NUnEVnp3PzJiaB?= Mn25SG1UVw>? MY\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{LrO|I2ODB7Mkm1
HBL-1 M37ISmNmdGxiVnnhZoltcXS7IFHzd4F6 NUP3OGt4OC13MECgcm0> NYToUnc5PzJiaB?= MlnxSG1UVw>? MnTr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFPVWZUzPTByOUK5OS=>
HLY-1 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIPRS2UxNTVyMDDuUS=> NIrMdIU4OiCq M{nNXGROW09? M2D3SYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1vsZVI2ODB7Mkm1
OCI-Ly3 NXf6cGVzS2WubDDWbYFjcWyrdImgRZN{[Xl? NGL5NFQxNTVyMDDuUS=> MmHWO|IhcA>? NELjPW5FVVOR MoG3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUmyOVAxQTJ7NR?=
OCI-Ly10 NXniNlZ6S2WubDDWbYFjcWyrdImgRZN{[Xl? NHm2cIgxNTVyMDDuUS=> NVHpfXNQPzJiaB?= MmjISG1UVw>? MoHE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4TOS|I2ODB7Mkm1
SU-DHL-4 NWrBPWdTS2WubDDWbYFjcWyrdImgRZN{[Xl? MXewMVUxOCCwTR?= NVn4b5NsPzJiaB?= M4i2SGROW09? NW\nT3dR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGLkfHUzPTByOUK5OS=>
SU-DHL-5 NXLp[pZYS2WubDDWbYFjcWyrdImgRZN{[Xl? MkPyNE02ODBibl2= NFvLRW84OiCq NYjBZXpGTE2VTx?= M1n0TYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXHIdlloOjVyMEmyPVU>
SU-DHL-6 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYPtN3ZKOC13MECgcm0> M1PX[FczKGh? MV\EUXNQ NWTuUXpy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXyyOVAxQTJ7NR?=
SU-DHL-10 NFHTWG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYTORVZpOC13MECgcm0> NWTxb3N1PzJiaB?= M1zFd2ROW09? Ml35[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoDzNlUxODl{OUW=
RC-K8 M4ny[WNmdGxiVnnhZoltcXS7IFHzd4F6 NG\abI8xNTVyMDDuUS=> MoP5O|IhcA>? NV;mOHJnTE2VTx?= M3PFVIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MViyOVAxQTJ7NR?=
OCI-Ly8 M{PDVmNmdGxiVnnhZoltcXS7IFHzd4F6 NXXYXGtDOC13MECgcm0> NX\6WYNTPzJiaB?= M3OyTGROW09? NH7nSWZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M33kcFI2ODB7Mkm1
OCL-Ly18 NXrHWVlUS2WubDDWbYFjcWyrdImgRZN{[Xl? NGPLR5kxNTVyMDDuUS=> MoLuO|IhcA>? NYjHS41xTE2VTx?= M{\ZSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYGyOVAxQTJ7NR?=
OCI-Ly3 M4HMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO3NVczNzJ3MD:1NFAhdk1? M3jONlIwPyCm M4XjNGROW09? Mnj6bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NInqU5EzPTByOUK5OS=>
OCI-Ly8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTuR2gyPzJxMkWwM|UxOCCwTR?= MUCyM|ch\A>? NVHJV2l{TE2VTx?= MWTpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi Ml;RNlUxODl{OUW=
SU-DHL-4 NG[xVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwVVE4Oi9{NUCvOVAxKG6P MmXuNk84KGR? NIOxR3FFVVOR NIfCTI9qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NXn3OnNbOjVyMEmyPVU>
SU-DHL-10 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xO|IwOjVyL{WwNEBvVQ>? NFTlV5QzNzdiZB?= NFPOVnNFVVOR NGPjO4NqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NVPIdnJMOjVyMEmyPVU>
OCI-Ly3 MlzoRZBweHSxc3nzJGF{e2G7 Mn\hNVczNzJ3MDDuUS=> NFvK[JM4\A>? NFO0W4ZFVVOR Mk\nbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MYGyOVAxQTJ7NR?=
OCI-Ly8 M{[4fWFxd3C2b4Ppd{BCe3OjeR?= M4\3[|E4Oi9{NUCgcm0> M{nmWldl MUDEUXNQ MkTzbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NHLPVW4zPTByOUK5OS=>
SU-DHL-4 MXnBdI9xfG:|aYOgRZN{[Xl? M2G1RlE4Oi9{NUCgcm0> M2Xv[Fdl M3ixZmROW09? NHHKS2hqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NYf5Z|ZbOjVyMEmyPVU>
SU-DHL-10 MlTtRZBweHSxc3nzJGF{e2G7 MXSxO|IwOjVyIH7N NUnMcIVPP2R? MXzEUXNQ M131OIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NEK4ZnozPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID